The Motley Fool

Two FTSE 100 growth stocks I’d buy with £2,000 today

Finding growth shares which trade at fair prices may now be easier after the FTSE 100’s recent pullback. The index fell by as much as 10% from its all-time high and while it has recovered around half of that, buying opportunities are still present.

With that in mind, here are two shares that appear to offer strong growth prospects for the long run. When combined with valuations that could move higher, this means they may be worth buying right now.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Takeover prospects

It’s been a busy few weeks for the management of rare diseases specialist Shire (LSE: SHP). The company has been the subject of takeover talk, with Takeda making three separate bids for the company. All of those have been rejected by the company’s management. However, a further bid from Takeda could be ahead, with industry peer Allergan announcing that it’s not considering making an offer.

One reason for the rival interest in Shire could be its relatively low valuation. Since it merged with Baxalta, investor sentiment towards the stock has been relatively weak. Even after a share price gain of 23% in the last month, it still has a price-to-earnings (P/E) ratio of around 11.

Given the company’s forecast growth rate of 7-8% over the next two financial years, it may prove to be undervalued. If a further bid is made, the company’s shares could deliver additional capital growth in the short run. And, should no further bids appear, its appeal from a value and growth perspective appears to be high. As such, now could be a sound moment to buy the stock for the long term.

Consistent growth

With the FTSE 100 having been volatile in recent months, investors may begin to place premium valuations on stocks that can offer consistent performance. One such company is medical devices sector specialist Smith & Nephew (LSE: SN). Unlike pharmaceutical stocks, it doesn’t experience a ‘boom and bust’ sales performance. Its sales are usually relatively consistent and this could provide a greater degree of certainty regarding its long-term performance.

Smith & Nephew is forecast to post a rise in its bottom line of 4% in the current year, followed by further growth of 7% next year. While not the highest rate of growth on offer in the FTSE 100, there’s a good chance of it meeting its prospects over the medium term. This reliability could become more highly sought-after by investors if market volatility remains high.

Beyond next year, the company appears to have a solid growth outlook. Demand for its range of products is likely to increase over the coming years as the world’s population increases in size and age. Given this potential tailwind, a P/E ratio of 21 seems to be a fair price to pay for the stock relative to its industry peers.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Peter Stephens has no position in any of the shares mentioned. The Motley Fool UK has recommended Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.